

PUBLICATIONS:

1. Kovacic JC, **Skelding KA**, Arya S, Ballard-Hernandez J, Goyal M, Ijioma NN, Kicielinski K, Takahashi EA, Ujueta F, Dangas G; American Heart Association Cardiovascular Interventions Science Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Council on Cardiovascular Radiology and Intervention Radial Access Approach to Peripheral Vascular Interventions: A Scientific Statement From the American Heart Association. *Circ Cardiovasc Interv*. 2024 Dec 4:e000094.
2. Vora AN, Batchelor WB, Boudoulas KD, Daggubati R, Elmariah S, Hermiller JB, Khalique O, Kliger C, Mahoney PD, **Skelding KA**, Smith TBBJ, Szerlip M, Goldsweig AM. Breaking Down Barriers to Transcatheter Aortic Valve Replacement. *JSCAI Vol3* (3) March 2024.
3. Brunton N, Best PJM, **Skelding KA**, Cendrowski EE. Spontaneous Coronary Artery Dissection (SCAD) from an Interventionalist Perspective. *Curr Cardiol Rep*. 2024 Mar;26(3):91-96. doi: 10.1007/s11886-023-02019-w. Epub 2024 Jan 18
4. **Skelding KA**, Kraev AS. Invited Commentary: Impact of New eGFR Equations on Risk Assessment in Patients Undergoing Transcatheter Aortic Valve Replacement. *Cardiovasc Revasc Med*. 2023 Apr;49:47-48. doi: 10.1016/j.carrev.2023.01.022. Epub 2023 Feb 1.
5. Writing Committee; Bass TA, Abbott JD, Mahmud E, Parikh SA, Aboulhosn J, Ashwath ML, Baranowski B, Bergersen L, Chaudry HI, Coylewright M, Denktas AE, Gupta K, Gutierrez JA, Haft J, Hawkins BM, Herrmann HC, Kapur NK, Kilic S, Lesser J, Lin CH, Mendirichaga R, Nkomo VT, Park LG, Phoubandith DR, Quader N, Rich MW, Rosenfield K, Sabri SS, Shames ML, Shernan SK, **Skelding KA**, Tamis-Holland J, Thourani VH, Tremmel JA, Uretsky S, Wageman J, Welt F, Whisenant BK, White CJ, Yong CM. 2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology (Coronary, Peripheral Vascular, and Structural Heart Interventions): A Report of the ACC Competency Management Committee. *JACC Cardiovasc Interv*. 2023 May 22;16(10):1239-1291.
6. Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, Mumtaz M, Olsen PS, Heiser JC, Merhi W, Kleiman NS, Chetcuti SJ, Gleason TG, Lee JS, Cheng W, Makkar RR, Crestanello J, George B, George I, Kodali S, Yakubov SJ, Serruys PW, Lange R, Piazza N, Williams MR, Oh JK, Adams DH, Li S, Reardon MJ; SURTAVI Trial Investigators. Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial. *JAMA Cardiol*. 2022 Oct 1;7(10):1000-1008.
7. Kern MJ, Applegate B, Bittl J, Block P, Butman S, Dehmer G, Garratt KN, Henry T, Hirshfeld J, Holmes DR Jr, Kaplan A, King S, Klein LW, Krucoff MW, Kutcher MA, Naidu SS, Pichard A, Ruiz CE, **Skelding KA**, Tobis JM, Tommaso C, Weiner BH, White

C. Conversations in cardiology: Late career transitions-Retool, retire, refocus. *Catheter Cardiovasc Interv.* 2022 Jun;99(7):2136-2144. doi: 10.1002/ccd.30210. Epub 2022 Apr

8. Naidu SS, Abbott JD, Bagai J, Blankenship J, Garcia S, Iqbal SN, Kaul P, Khuddus MA, Kirkwood L, Manoukian SV, Patel MR, Skelding K, Slotwimer S, Swaminathan RV, Welt FG, Kolansky DM. SCAI expert consensus update on best practices in the cardiac catheterization laboratory. *CCI*, Published online April 28, 2021.
9. Yu J, Park K, Chandrasekhar J, Kalkman DN, Johnson JA, Wild RA, Dobies D, Thomas L, Skelding KA, Ahmed B, Barber KR, Mungee S, Mehran R. Feasibility and Utility of a Cardiovascular Risk Screening Tool in Women Undergoing Routine Gynecology Evaluation. *Journal of Women's Health* 2020 Vol 00; 00.
10. Harjai KJ, Bules T, Berger A, Young B, Singh D, Carter R, Agarwal S, Crockett S, Mascarenhas V, Nawaz Y, Stella J, Burnside J, **Skelding KA**, Desciak M, Casale AS; Transcatheter Interventions at GEisinger Structural (TIGERS) Registry, Geisinger Health System, Pennsylvania. Efficiency, Safety, and Quality of Life After Transcatheter Aortic Valve Implantation Performed With Moderate Sedation Versus General Anesthesia. *Am J Cardiol.* 2020 Apr 1;125(7):1088-1095
11. Van Mieghem NM, Popma JJ, Deeb GM, Yakubov SJ, Serruys PW, Windecker S, Søndergaard L, Mumtaz M, Gada H, Chetcuti S, Kleiman NS, Kodali S, George I, Teefy P, Kiaii B, Oh JK, Kappetein AP, Chang Y, Mugglin AS, Reardon MJ; SURTAVI Trial Investigators. Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. *JACC Cardiovasc Interv.* 2020 Feb 10;13(3):323-331
12. Jasper R, Skelding K. Cardiovascular disease risk unmasked by pregnancy complications. *Eur J Intern Med* 2018 July 25.
13. Pancholy MS, Skelding K, Scott T, Blankenship J, Pancholy SB. Effect of access site choice on acute kidney injury after percutaneous coronary intervention. *Am J Cardiol* 2017.
14. Madonis SM, Skelding KA, Roberts M. Management of acute coronary syndromes: special considerations in women. *Heart* 2017.
15. Agarwal S, Thakkar B, Skelding KA, Blankenship JC. Trends and outcomes after same day discharge after percutaneous coronary interventions. *Circ Cardiovasc Qual Outcomes.* 2017.
16. Al-Azizi KM, Skelding KA. Renin angiotensin system inhibitors: a panacea for heart disease? *J Thorac Dis* June 9(6) 1437-1439.
17. Reardon MJ et al. Surgical or Transcatheter Aortic Valve Replacement in Intermediate Risk Patients. *N Engl J Med* 2017 April 6;376(14) 1321-1331.

18. Grines CL, Skelding KA. Women and Calcium: A Love-Hate Relationship at the Center of the Heart. *JACC Cardiovasc Interv* 2016.
19. Dewey FE et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. *Science* 2016 Dec 23;354(6319).
20. Kleinman NS et al. Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors: A Report From the Corevalve Trials. *Circ Cardiovasc Interv* 2016.
21. Skelding KA et al. Transcatheter Aortic Valve Replacement Versus Surgery in Women at High Risk for Surgical Aortic Valve Replacement (from the CoreValve US High Risk Pivotal Trial). *Am J Cardiol* 2016.
22. Forrest JK et al. Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). *Am J Cardiol* 2016.
23. Kahlon TS et al. Impact of pre-hospital electrocardiograms on time to treatment and one year outcome in a rural regional ST-segment elevation myocardial infarction network. *Catheter Cardiovasc Interv* 2017.
24. Baber U et al. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. *Coron Artery Dis* 2016.
25. Yeh RW et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. *JAMA* 2016.
26. Ellis SG et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. *N Engl J Med* 2015.
27. Wang TY et al. Women in interventional cardiology: Update in percutaneous coronary intervention practice patterns and outcomes of female operators from the National Cardiovascular Data Registry. *Catheter Cardiovasc Interv* 2016.
28. Berger PB, Kirchner HL, Wagner ES, Ismail-Sayed I, Yahya S, Benoit C, Blankenship JC, Carter R, Casale AS, Green SM, Scott TD, Skelding KA, Woods E, Henry YM. Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery? *Journal of Interventional Cardiology* 28(3):223-232, 2015 Jun.
29. Kereiakas DJ et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. *JAMA* 2015.
30. Skelding KA and Tremmel J. Arterial and Venous Access. *The Cardiac Catheterization Handbook* 6th edition. Saunders 2015

31. Baker NC, O'Connell EW, Htun WW, Sun H, Gree SM, **Skelding KA**, Blankenship JC, Scott TD, Berger PB. Safety of coronary angiography and percutaneous coronary intervention via the radial versus femoral route in patients on uninterrupted oral anticoagulation with warfarin. *Am Heart J*. 2014 Oct;168(4):537-44.
32. Mauri L et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med*. 2014.
33. Reddy VY et al. Percutaneous left atrial appendage closure vs. warfarin for atrial fibrillation: a randomized clinical trial. *JAMA* 2014.
34. Adams DH et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014.
35. Popma JJ et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol* 2014.
36. Kumar, Arun H.S.; Martin, Kenneth; Doyle, Brendan; Huang, Chien-Ling; Pillai, Gopala-Krishnan M.; Ali, Mohammed T.; **Skelding, Kimberly A.**; Wang, Shaohua; Gleeson, Birgitta M.; Jahangeer, Saleem; Ritman, Erik L.; Russell, Stephen J.; Caplice, Noel M. Intravascular cell delivery device for therapeutic VEGF-induced angiogenesis in chronic vascular occlusion. *Biomaterials* 35 (2014) 9012-9022.
37. Rao, S.A.; Tremmel J.A.; Gilchrist I.C.; Shah, P.B.; Gulati, R.; Shroff, A. R.; Crisco, V.; Woody, W.; Zoghbi, G.; Duffy, P. L.; Sanghvi, K.; Krucoff, M.W.; Pyne, C.T.; **Skelding, K.A.**; Patel, T.; and Pancholy, S.B. Best practices for transradial angiography and interventions: A consensus statement from the society for cardiovascular angiography and intervention's transradial working group. *Catheterization and Cardiovascular Interventions*, February 2014, Vol 83, Issue 2, pp 228-236.
38. Hess CN, Rao SV, Skelding KA, Kern MJ, Krucoff MW. *The Interventional Cardiac Catheterization Handbook 3rd Edition*. Saunders 2013.
39. Yost, Gregory W; Puher, Stephanie L; Graham, Jove; Scott, Thomas D; **Skelding, Kimberly A**; Berger, Peter B; Blankenship, James C. Readmission in the 30 Days after Percutaneous Coronary Intervention. *J Am Coll Cardiol Interv*. 2013;6(3):245doi:10.1016/j.jcin.2012.12.119.
40. Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, **Skelding KA**, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V everolimus-eluting and Taxus Express2 paclitaxel-eluting coronary stents in patients with jailed side branches from the SPIRIT IV trial at 2 years. *American Journal of Cardiology*. 111(11): 1580-6, 2013 Jun 1.
41. **Skelding, K. A.**, Boga, G., Sartorius, J., WOOD, G. C., Berger, P. B., Mascarenhas, V. H., Good, C. W., Scott, T. D. and Blankenship, J. C. (2012), Frequency of Coronary Angiography and Revascularization among Men and Women with Myocardial Infarction

and Their Relationship to Mortality at One Year: An Analysis of the Geisinger Myocardial Infarction Cohort. (J Interv Cardiol 2013; Feb, Vol. 26. Issue 1; pp 14-21).

42. Suryadevara, Ramya, **Skelding, Kimberly**. Vascular Complications in Women and the Radial Approach. *Interventional Cardiology Clinics*: April 2012; 207-11.
43. Suryadevara, Ramya, **Skelding, Kimberly**. Radial Access for Coronary Angiography and Percutaneous Coronary Artery Intervention, a step by step guide to this technique and best practices. *Cardiac Interventions Today*, Oct 2012; 64-69.
44. Al Muradi HA, Mehra A, Okolo J, Vlachos H, Selzer F, Marroquin O, **Skelding K**, Holper E, Williams D, Abbott JD. Clinical presentation and predictors of target vessel revascularization after drug-eluting stent implantation. *Cardiovascular Revascularization Medicine* 13 (2012) 311-315.
45. Crudu V, Sartorius J, Berger PB, Scott T, **Skelding K**, Blankenship JC, Middle-of-the-night PCI does not affect subsequent day PCI success and complication rates by the same operator. *Cathet Cardiovasc Interv* 2012;80:1149-1154.
46. Buchanan G, Chieffo A, Mehilli J, Mikhail G, Mauri F, Presbitero P, Grinfeld L, Petronio A, **Skelding K**, Hoyer A, Mehran R, Morice M, for the Women In Innovation Group. The occupational effects of interventional cardiology: results from the WIN for Safety survey. *EuroIntervention*, September 2012.
47. Kern MJ and Skelding KA. Arterial and Venous Access. *The Cardiac Catheterization Handbook* 5th edition. Saunders 2011
48. Caputo RP, Tremmel JA, Rao S, Gilchrist IC, Pyne C, Pancholy S, Frasier D, Gulati R, **Skelding K**, Bertrand O, Patel T. Transradial arterial access for coronary and peripheral procedures: executive summary by the Transradial Committee of the SCAI. *Catheterization and Cardiovascular Interventions*. 78(6):823-39, 2011 Nov 15.
49. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. *N Engl J Med* 2011.
50. Lansky, Alexandra J.; Yaqub, Manejeh; Sood, Poornima; Ying, Shi-Wa; Wang, John; Caputo, Ronald; Farhat, Naim; Applegate, Robert J.; **Skelding, Kimberly A.**; Kereiakes, Dean J.; Sudhir, Krishnankutty; Stone, Gregg W.; Performance of everolimus-eluting and paclitaxel-eluting coronary stents in women: 2 year outcomes from the SPIRIT IV trial. *Cardiovascular Revascularization Medicine*-May 2011 (Vol. 12, Issue 3, Page e9, DOI: 10.1016/j.carrev.2011.04.267).
51. Acharya Y, Bhattarai J, Berger P, **Skelding K**, Scott T, Hodgson J, Blankenship J. High dose adenosine for no-reflow after percutaneous coronary intervention is safe and effective but may induce atrial fibrillation. *Cathet Cardiovasc Intervent* 2011;77:S115.

52. Crudu V, Blankenship J, Berger P, Scott T, **Skelding K**. Complications related to access site after percutaneous coronary interventions: are the adverse events underreported? *Cathet Cardiovasc Intervent* 2011; 77:643-7.
53. Yost G, Blankenship JC, Scott TD, **Skelding KA**, Nardone D, Hodgson JM, Berger PB. Frequency and etiology of readmission in the 30 days after a percutaneous coronary intervention. *Cathet Cardiovasc Intervent* 2011;77:S81.
54. Yost GW, Puher SL, Scott SD, **Skelding KA**, Nardone D, Hodgson JMcB, Berger PB, Blankenship JB. The frequency and etiology of readmission in the 30 days after percutaneous coronary intervention. *J Am Coll Cardiol* 2011;58:B107.
55. Haftbaradaran H, Scott T, **Skelding K**, Nardone D, Hodgson J, Berger P, Blankenship J, Etiology of in-hospital death after PCI in the current era. *Cathet Cardiovasc Intervent* 2011;77:S10.
56. Ganesh SK, Joo J, **Skelding KA**, Mehta L, Zheng G, O'Neill K, Billings EM, Helgadottir A, Anderson K, Thorgeirsson G, Gundason T, Geller NL, Simari RD, Holmes DR, O'Neill WW and Nabel EG. Time Course Analysis of Gene Expression Identifies Multiple Genes with Differential Expression in Patients with In-Stent Restenosis; *BMC Med Genomics*. 2011; 4: 20.
57. Caputo RP et al. Transradial arterial access for coronary and peripheral procedures: executive summary by the Transradial Committee of the SCAI. *Catheter Cardiovasc Interv* 2011.
58. Best PJ, **Skelding KA**, Mehran R, Chieffo A, Kunadian V, Madan M, Mikhail GW, Mauri F, Takahashi S, Honye J, Hernandez-Antolin R, Weiner BH, and on behalf of the Women in Innovations (WIN) group of the Society of Cardiac Angiography Intervention. SCAI Consensus Document on Occupational Radiation Exposure to the Pregnant Cardiologist and Technical Personnel. *Catheter Cardiovascular Interv*. 2011 Feb 1;77(2):232-41, *Eurointervention* 6(7):866-74, 2011, *Heart, Lung & Circulation* 20(2):83-90, 2011.
59. Blankenship JC, Scott TD, **Skelding KA**, Haldis TA, Tompkins-Weber K, Sledgen MY, et al. Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. *J Am Coll Cardiol*. 2011 Jan 18;57(3):272-9.
60. Blankenship JC, **Skelding KA**, Scott TD, Berger PB, Parise H, Brodie BR, Witzenbichler B, Gaugliumi G, Peruga JZ, Lanskey AJ, Mehran R. and Stone GW. Predictors of Reperfusion Delay in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention from the Horizons-AMI Trial; *American Journal of Cardiology* 2010 Dec 1;106(11):1527-33.
61. **Skelding KA**, Gerhard GS, Vlachos H, Selzer F, Kelsey SF, Chu X, Erdman R, Williams DO, Kip KE. Association of an INSIG2 obesity allele with cardiovascular phenotypes is gender and age dependent. *BMC Cardiovascular Disord*. 2010 Sep 29;10:46.

62. Bossaert L et al. Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. *Circulation* 2010.
63. Stone GW et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med* 2010.
64. Chieffo A, Hoyer A, Mauri F, Mikhail GW, Ammerer M, Grines C, Grinfeld L, Madan M, Presbitero P, **Skelding K**, Weiner BH, Mehran R, WIN Group. Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative. *Eurointervention*. 5(7):773-9, 2010 Feb, *Revista Espanola de Cardiologia*. 63(2):200-8, 2010 Feb, *Catheterization & Cardiovascular Interventions*. 75(2):145-52, 2010 Feb 1.
65. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. *Circ Cardiovasc Interv*. 2009.
66. Kalyanasundaram A, Gerhard GS, **Skelding KA**. Genomics, haplotypes and cardiovascular disease. *Future Cardiology* 2007 Nov;3(6):601-10.
67. Klein LW, Sheldon MW, Brinker J, Mixon TA, **Skelding K**, Strunk AO, Tommaso CL, Weiner B, Bailey SR, Uretsky B, Kern M, Laskey W, Interventional Committee of the Society for Cardiovascular Angiography and Interventions. The Use of Radiographic Contrast Media during PCI: a Focused Review: a Position Statement of the Society of Cardiovascular Angiography and Interventions. *Catheterization & Cardiovascular Interventions* 74(5):728-46, 2009 Nov 1.
68. Blankenship JC, **Skelding KA**, Scott TD, Buckley J, Zimmerman DK, Temple A, Sartorius J, Jimenez E, Berger PB. ST-elevation myocardial infarction patients can be enrolled in randomized trials before emergent coronary intervention without sacrificing door-to-balloon time. *Am Heart J* 2009;158:400-407.
69. Lokhandwala Jazar O. and **Skelding Kimberly A.**; Sex Differences in Percutaneous Coronary Interventions; *Journal of Cardiovascular Translational Research*: Volume 2, Issue 3 (2009), p. 300.
70. Holmes DR. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet* 2009.
71. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. *Circulation* 2009.
72. Lokhandwala Jazar O., Best Patricia J.M., Butterfield Joseph H., **Skelding Kimberly A.**, Scott Thomas, Blankenship James C., Buckley Jeremy W., and Berger Peter B.

Frequency of Allergic or Hematologic Adverse Reactions to Ticlopidine Among Patients With Allergic or Hematologic Adverse Reactions to Clopidogrel; *Circ Cardiovasc Intervent.* published 22 July 2009.

73. Cai, Q.; **Skelding, K.**; Armstrong Jr, A.; Desai, D.; Wood, G.C.; Blankenship, J. Predictors of long-term major adverse cardiac events and clinical restenosis following elective percutaneous coronary stenting. *Angiology*, April 2009; 60:141-7, 2009.
74. Good Christopher W., Blankenship James C., Scott Thomas D., **Skelding Kimberly A.**, Berger Peter B., Wood G.Craig. Feasibility and Safety of Ad Hoc Percutaneous Coronary Intervention in the Modern Era, *J Invasive Cardiol.* 2009 May;21(5): 194-200..
75. Cai Qiangjun, **Skelding Kimberly**, Armstrong Jr. Arthur, Desai Dipan, Wood G. Craig, Blankenship James. Predictors of Long-Term Major Adverse Cardiac Events and Clinical Restenosis Following Elective Percutaneous Coronary Stenting. *Angiology.* 2009; 60:141-147.
76. Hubbard CR, Blankenship JC, Scott TD, **Skelding KA**, Berger PB. Emergency pretreatment for contrast allergy before direct percutaneous coronary intervention for ST-elevation myocardial infarction. *Am J Card* 2008; 102:1469-1472.
77. Blankenship JC and **Skelding KA**. Rapid Triage, Transfer, and Treatment with Percutaneous Coronary Intervention for Patients with ST-Segment Elevation Myocardial Infarction. *Acute Coronary Syndromes* 2008;9(2):59-65.
78. Wood GC, Still CD, Chu X, Susek M, Erdman R, Hartman C, Yeager S, Blosky MA, Krum W, Carey DJ, **Skelding KA**, Benotti P, Stewart WF, Gerhard GS. Association of Chromosome 9p21 SNPs with cardiovascular phenotypes in morbid obesity using Electronic health record data. *Genomic Med.* 2008 Jan;2(1-2):33-43. Epub 2008 Jul 26.
79. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khatktab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, **Skelding KA**, Dirschinger J, Richardt G, Berger PB, Schomia A; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. *N Engl J Med*, 2008 Aug 14;359(7):688-96. Erratum in: *N Engl J Med.* 2008 Aug 28;359(9):983.
80. Kastrati A et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. *N Engl J Med* 2008.
81. Doroodchi H, Abdolrasulnia M, Foster JA, Foster E, Turakhia MP, **Skelding KA**, Sagar K, Casebeer LL. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. *BMC Fam Pract.* 2008 Jul 8;9:42.
82. Blankenship JC, Sledgen M, **Skelding KA**, Scott T, Berger P, Sartorius JA, Donegan M, Menapace FJ. Efficient referring hospitals can routinely transfer patients for STEMI PCI with door-to-balloon times <90 minutes. *JAM Coll Cardiol* 2008; 51:A267 (Abstr).

83. Blankenship JC, Haldis TA, Wood GC, **Skelding, KA**, Scott T, Menapace FJ. Rapid Triage and Transport of Patients with ST-Elevation Myocardial Infarction for Percutaneous Coronary Intervention in a Rural Health System. *Am J Cardiol* 2007;100-944-948
84. **Skelding KA**, Best PJM, Bartholomew BA, Lennon RJ, O'Neill WW, Rihal CS. Validation of a Predictive Risk Score for Radiocontrast Induced Nephropathy Following Percutaneous Coronary Intervention. *J Invasive Cardiol*, 2007;19:229-233
85. **Skelding KA** and Berger PB. Review: Rescue percutaneous coronary intervention but not repeated fibrinolysis is effective for failed fibrinolysis in STEMI. *ACP Journal Club* 2007. Evidence based journals, ACP-ASIM. May 22, 2007
<http://www.acpjcc.org/Preview/1/1/Issue/ACPJC-2008-147-1-011.htm>
86. **Skelding KA**, Gerhard GS, Simari RD, Holmes DR. The effect of HapMap on cardiovascular research and clinical practice. *Nat Clin Pract Cardiovasc Med*. 2007 Mar;4(3):136-142.
87. **Skelding KA** and Hubbard CR. Spontaneous Coronary Artery Dissection Related to Menstruation—Case Report and Review, *Journal of Invasive Cardiology*. *J. Invasive Cardiol* 2007;19:E174-E177.
88. Cai Q, **Skelding KA**, Armstrong AT Jr, Desai D, Wood GC, Blankenship JC. Predictors of periprocedural creatinine kinase-myocardial band elevation complicating elective percutaneous coronary intervention. *Am J Cardiol*. 2007 Mar 1;99(5):616-620.
89. Kalyanasundaram A, **Skelding KA**, Berger PB. The Value of Registries and the Importance of Evidence- Based Medicine. *J Invasive Cardiol*. 2006;118: 11F-16F.
90. Mehta L, Devlin W, McCullough PA, O'Neill WW, **Skelding KA**, Stone GW, Boura JA, Grines CL, Impact of Body Mass Index on Outcomes After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction. *Am J Cardiol* 2007;99:906-910.
91. **Skelding K**, Berger PB. Does clopidogrel pretreatment counteract the benefits of off-pump CABG surgery? *Nat Clin Pract Cardiovasc Med*. 2006 Oct;3(10):530-53
92. **Skelding KA**, Klein LW. SCAI membership survey of the 2005 AHA/ACC/SCAI PCI guideline: A summary report from the interventional committee, *Catheter Cardiovasc Interv*. 2006 Jul;68(1):173-80.
93. Deb A, Wang SH, **Skelding K**, Miller D, Simper D, Caplice N. Bone marrow-derived Myofibroblasts are present in adult human heart valves. *J Heart Valve Dis*. 2005 Sept;14(5):674-678.
94. **Skelding KA**, Young JJ. Evolving use of drug-eluting stents in diabetic patients. *J Invasive Cardiol*. 2005 Jul;17(7):349-351

95. Ganesh SK, **Skelding KA**, Mehta L, O'Neill K, Joo J, Zheng G, Goldstein JA, Simari R, Billings E, Geller NL, Holmes D, O'Neill WW, Nabel EG. Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. *Pharmacogenomics*. 2004 Oct;5(7):949-1004
96. Deb A, **Skelding KA**, Wang S, Reeder M, Simper D, Caplice NM. Integrin Profile and In Vivo Homing of Human Smooth Muscle Progenitor Cells. *Circulation* 2004; 110,(17):2673-2677.
97. Deb A, Wang S, **Skelding KA**, Miller D, Simper D, Caplice NM. Quantifying chimeric cardiomyocytes. *Circulation* 2003 Mar 11;107(9):1247-1249.
98. Deb A, Wang S, **Skelding KA**, Miller D, Simper D, Caplice NM. Bone Marrow-Derived Cardiomyocytes Are Present in Adult Human Heart: A Study of Gender-Mismatched Bone Marrow Transplantation Patients. *Circulation* 2003;107:1245-1247.
99. Kim TH, **Skelding KA**, Nabel EG, Simari RD. What can cardiovascular gene transfer learn from genomics: and vice versa? *Physiol Genomics*. 2002 Dec 3;11(3):179-182.
100. Bonzeim KA and **Skelding KA**. Valvular Heart Disease. In Ehrman, JK, Gordon, PM, Visich PS, Ketyian SJ, eds. *Clinical Physiology*. 1st edition. Champaign, IL: Human Kinetics; 2003:243-260.
101. **Skelding KA**, Goldstein JA, Lee D, Mehta L, Pica MC, O'Neill WW. Resolution of Refractory No-Reflow After Intracoronary Epinephrine. *Catheter Cardiovasc Interv* 2002 Nov;57(3):305-309.
102. **Skelding KA**, Mehta LS, Pica MC, Finta B, Shoukfeh M, Grines CL, O'Neill WW, Kahn JK Primary Percutaneous Interventions for Acute Myocardial Infarctions in Octogenarians: A Single Center Experience *Clin Cardiol*. 2002 Aug;25(8):363-6.
103. Dixon SR, **Skelding KA**, Frumin HI, O'Neill WW. Occlusion of a Saphenous Vein Graft Aneurysm with a Vein-Covered Stent *J Interv Cardiol*. 2002 Jun; 15(3):201-4.

ABSTRACTS:

1. References incomplete.
2. Rasania SP, Suryadevara R, Brown E, Berger P, Green S, Scott T, **Skelding K**, Feng W, Blankenship J, Geisinger Health System, Danville, PA and Vidant Medical Center, Greenville, NC. A Randomized Controlled Trial to Assess Operator Radiation Exposure From Cardiac Catheterization Procedures Using a RAD BOARD® with Standard Pelvic Shielding vs. Standard Pelvic Shielding Alone. Society for Cardiovascular Angiography and Interventions Foundation, San Diego, CA, May 2015.

3. Caplice N, Doyle B, Kumar A, Martin K, Ali M, **Skelding K**, Wang S, Gleeson B, Ritman E, Russell S. Stent-Based Vascular Cell Delivery for Therapeutic VEGF-Induced Angiogenesis. *Circulation*. 2013; 128:A19131.
4. Blankenship JC, Scott T, **Skelding KA**, Haldis TA, Tompkins-Weber K, Sledgen M, Donegan M, Buckley J, Sartorius JA, Hodgson J, Berger P. Door-to-Balloon Times Under 90 Minutes Can be Routinely Achieved for Patients Transferred for ST-Segment Elevation Myocardial Infarction Percutaneous Coronary Intervention in a Rural Setting. *J. Am. Coll. Cardiol*. 2011; 57:272-279.
5. Crudu V, Blankenship J, **Skelding K**. Predictors of Complications Related to Access Site After Percutaneous Coronary Interventions. *Journal of the American College of Cardiology*. 2010 Sept 21;56(13):B118.
6. Crudu V, Blankenship J, Berger P, Scott T, **Skelding K**. Operator Sleep Deprivation from Late-Night STEMI PCI does not Increase Next-Day PCI Complication Rates. *Journal of the American College of Cardiology*. 2010 Sept 21;56(13):B118.
7. Crudu V, Blankenship J, Berger P, Scott T, **Skelding K**. Complications Related to Access Site after Percutaneous Coronary Interventions: Are the Adverse Events Underreported? *Catheterization and Cardiovascular Interventions*. 2010 May 1;75(6):S156.
8. **Skelding, Kimberly A.**; Gerhard, Glenn S.; Vlachos, Helen; Selzer, Faith; Kelsey, Sheryl F.; Williams, David O.; Kip, Kevin E. INSIG2 Association with Cardiovascular Phenotypes in Older Adults, 2009.
9. Berger P., Blankenship J., Buckley J., Scott T., **Skelding K.**, Zimmerman D., PCI relief of angina is similar for typical versus atypical symptoms. *Cath Cardiovasc Intervent* 2009; 73:S56.
10. Blankenship JC, Sartorius JA, Zimmerman DK, **Skelding KA**, Scott TA, Belles LM, Temple A, Berger PB. Enrollment in STEMI PCI trials is possible without increase in door to balloon times. *J Am Coll Cardiol* 2009;53:A51 (Abstr).
11. Blankenship JC, **Skelding KA**, Scott TD, Berger PB, Parise H, Brodie BR, Witzenberger B, Gaugliumi G, Peruga JZ, Lansky AJ, Mehran R and Stone GW. Presentation to Non-PCI Hospital is Major Modifiable Factor Associated with Delayed Door-to-Balloon Time in Horizons-AMI. American Heart Association Scientific Sessions 2008.
12. Zimmerman DK, Blankenship JC, **Skelding KA**. Symptoms After Stenting are Unrelated to Symptoms Before or During Stenting. *Circulation* 2007 Oct;116(16):II677. American Heart Associations Scientific Sessions 2007
13. Blankenship JC, Sledgen M, Berger PB, Wood GC, **Skelding KA**, Scott T, Menapace FJ. Can STEMI Patients Transferred for Primary Angioplasty Receive Treatment Within 90-Minutes in a Rural Setting. *Circulation* 2007 Oct;116(16):II431. American Heart Associations Scientific Sessions 2007.

14. Marino CA, Hubbard CR, Good C, Mascarenhas V, Wood Craig, Scott TD, Blankenship JC, Berger PB, **Skelding KA**. Hemoglobin is Not Associated with 1 Year Mortality in Patients with Myocardial Infarction. American Heart Association-Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2008.
15. Doroodchi H, Abdolrasulnia M, Foster JA, Foster E, Turakhia MP, **Skelding KA**, Sagar K, Casebeer LL. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract 2008 July 8.
16. Santhi K Ganesh, **Kimberly A. Skelding**; Jungnam Joo, Gang Zheng, Adong Yu, Nancy Geller, Stephen Pan, Eric Billings, Laxmi Mehta, Kathleen O'Neill, Robert Simari, David Holmes, Jr; William O'Neill; Giulia Kennedy; Elizabeth G. Nabel. Candidate Genes for Vascular Remodeling Identified Through a Genome-Wide Association Study of In-Stent Restenosis. Cardiovascular Genomics Meeting, Cold Spring Harbor, NY 2007.
17. Nolan R and **Skelding KA**. Creating the Business Case for a Women and Heart Disease Program. Nursing Management Congress 2007.
18. Good C **W** Patterson, J Blankenship J, Scott T, Carey B, Wywadis R, **Skelding KA** Analysis of Patients at High risk of Developing contrast-Induced Nephropathy. Society for Cardiovascular Angiography and Interventions, 30th Annual Scientific Sessions, May 2007.
19. Brofferio A, **Skelding KA**, Blankenship J, Wood C. Gender Differences in Risk Factors Profile in patients Undergoing Cardiac Catheterization. Society for Cardiovascular Angiography and Intervention Annual Sessions 2006.
20. Carey B, Blankenship J, **Skelding KA**, Sledgen M and Singh K. Rural Patients Transferred for Stemi PCI Can Meet the 90-Minutes Door-To-Balloon Time Guidelines Goal. Society for Cardiovascular Angiography and Intervention Annual Sessions 2006.
21. Ganesh K, **Skelding KA**, Joo, J, Zheng G, A Yu, Geller N, Pan S, Billings E, Mehta L, O'Neill K, Simari R, Holmes D, Jr; O'Neill W, Kennedy G, Nabel E. Candidate Susceptibility Loci for Vascular Remodeling Identified Through Genomewide Association Study of In-Stent Restenosis. Atherosclerosis, Thrombosis and Vascular Biology, Scientific Sessions 2007.
22. Ganesh S, **Skelding KA**, Joo J, Zheng G, Yu A, Geller N, Pan S, Billings E, Mehta L, O'Neill K., Simari R, Holmes, D Jr., O'Neill WW, Kennedy GC, Nabel E, Genome Wide Association Study of In-Stent Restenosis Identifies Multiple Candidate Susceptibility Loci American Heart Association Scientific Sessions, 2006.
23. Hubbard C, Shirani J, Nassef L and **Skelding KA**, Dobutamine-induced ST-segment Elevation in the Absence of Prior Infarction is a Marker of Viable, Collateral-Dependent Myocardium American Society of Echocardiography, 2007

24. **Skelding KA**, O'Neill K, O'Neill WW, Goldstein **JA**, Myonecrosis Commonly Complicates No-Reflow Developing After Interventions in Both Native Coronary Vessels and Vein Grafts. Society for Coronary Angiography and Intervention. Annual Scientific Sessions, 2002.
25. **Skelding KA**, Mehta L Demetriou D, Crisan D, Boura JA, Grines C, O'Neill **WW**. Two Year Outcomes Following Percutaneous Intervention: Beaumont Angiotensin Converting Enzyme Genotype and Endpoints Trial (The BAGET trial). American College of Cardiology Scientific Sessions, 2002.
26. **Skelding KA**, Harjai K, Mehta L, Stone GW, Cox D, Boura J, Grines L, O'Neill WW, . Grines **C**. Gender is an Independent Predictor of Both In Hospital and 1 Year Outcome Following Primary Primary Intervention for Myocardial Infarction. American College of Cardiology Scientific Sessions, 2002.
27. **Skelding KA**, Coronary Spasm – Pathophysiology and Presentation. Michigan American College of Cardiology Clinical Vignette Competition, August 2001.
28. Fejka M, **Skelding KA**, Corpus RJ, Arends, J, O'Neill WW, Franklin **BA**. Exercise Induced Non-sustained Ventricular Tachycardia-A Significant marker of Coronary Artery Stenosis. Poster Presentation, American College of Sports Medicine, June 2001.
29. **Skelding KA**, Demetriou D, Mehta L, Crisan D, Guido-Allen DA, Boura JA, Finta B Pica MC, Safian RD, Grines CL, Goldstein JA, O'Neill **WW**. D/D Angiotensin converting Enzyme Genotype Increases Target Vessel Revascularization in Diabetic Patients. Poster Presentation, American College of Cardiology Scientific Sessions, March 2001. Research Competition, Michigan Chapter of the American College of Cardiology, October 2001, First Runner Up.
30. **Skelding KA**, Demetriou D, Crisan D, Boura, JA, Pica MC, Guido-Allen DA, Finta B, Mehta L, Safian RD, Grines CL, Goldstein JA, O'Neill WW. Platelet Glycoprotein III a Polymorphism is Not a Risk Factor for Target Vessel Revascularization After Percutaneous Revascularization. Poster Presentation, American College of Cardiology Scientific Sessions, 2001.
31. **Skelding KA**, Goldstein J, Lee D, Mehta L, Pica MC, O'Neill **WW**. Resolution of Refractory No-Reflow After Intracoronary Epinephrine. Poster Presentation, American Heart Association Scientific Sessions, November 2000.
32. **Skelding KA**, Mehta L, Boura JA, Pica MC, Finta B, Shoukfeh M, Grines CL, O'Neill WW, Kahn JL. Percutaneous Interventions for Acute Myocardial Infarctions in Octogenarians-The Beaumont Experience Poster Presentation Transcatheter Therapeutics Conference, October 2000 Oral Presentation, William Beaumont Hospital Research Forum, June 2000.
33. **Skelding KA**, Cronin L, Franklin **BA**. Arrhythmias After Exercise and Cold Water – A Case Report. Oral Presentation, American College of Sports Medicine, June 2000.

LECTURES:

1. Faculty Lecturer Motown Women's Heart Symposium 2022.
2. Women's Cardiometabolic Health and Wellness Masterclass 2022
3. Faculty Lectures Society for Coronary Angiography and Intervention 2003- present.
4. Faculty Lectures American College of Cardiology, 2001-present.
5. Faculty Lectures Transcatheter Therapeutics, 2004-present.
6. Faculty Lectures Cardiovascular Revascularization Therapeutics 2010-present
7. SCAI Special Symposium: Complex Cardiovascular Interventions, Scientific Sessions 2015.
8. Fellows Lecture Series-Geisinger Medical Center, 2005-2017.
9. TCT Live Case Moderator & Commentator 2012-2014.
10. 14th Annual Nursing Symposium: Lessons from the Heart, TAVI: Breakthroughs in Care –2015.
11. Women & Heart Disease, Health Leaders Media –, 2013.
12. Updates in Heart Disease, Public Library for Union County, November, 2012.
13. Radial Puncture Technique, TRICO, Ahmedabad, India, 2012.
14. Transradial Basics, TCT 2012, Miami, Florida, 2012.
15. Women and Heart Disease-Has the Gender Gap Narrowed, Cardiology Symposium, Bangor, Maine, 2012.
16. Radial Arterial Catheterization; How to and why?, Cardiology Symposium, Bangor, Maine, 2012.
17. Gender differences in the treatment of AMI. Her at Heart, London, England, 2012.
18. Women and Heart Disease: Is it ever too early to think about? Penn State Panhellenic Council, State College, PA, 2012.
19. Personalized PCI, Medscape, Orlando, Florida, November 2011
20. Transradial Intervention for STEMI/ACS: Does it Rival the Trans-Femoral Approach?, Incidence & Risk of Periprocedure Bleeding and Impact of TRI, Starting a Radial Artery Program; Advancing Stemi Care beyond D2B, Dallas, Texas, 2011.
21. Transradial Diagnostic Coronary Angiography: Catheter Selection, Techniques, Tips and Tricks; SCAI Annual Scientific Sessions, 2011
22. Radial Access: Should it be our First Choice for Coronary Intervention Annual Concepts in Contemporary Medicine Symposium 2011 Houston, Texas, 2011
23. WIN's activities, Outreach to Women with Cardiovascular Disease, Fostering the Professional Development of Female Interventional and Invasive Cardiologists and How to Best Treat the Disparities for Women with Cardiovascular Disease Society for Vascular Surgery 2011
24. Examining Patient Options: How Evolution in Stent Technology Will Change Treatment American College of Cardiology Scientific Sessions, 2011.
25. Radial Artery Catheterization Help or Hype Grand Rounds Speaker, Brown University-Rhode Island Hospital, 2011.
26. 19th Annual Topics in the Tropics, What's New in Heart Disease, December 2010.
27. 19th Annual Topics in the Tropics, ECG Workshop, December 2010.
28. Society for Cardiovascular Angiography and Interventions; Managing Radiation and Contrast Use with TRA/I, 2010.
29. TRICO: Complications of Transradial Arterial Procedures, Ahmedabad, India, 2010.

30. TRICO: Live Case Moderator, Ahmedabad, India, 2010.
31. Women In Interventional Cardiology: Underrepresentation of Women in Clinical Trials: What does this mean and what can we do? Radial Approach to PCI – An Update, 2010.
32. Transcatheter Cardiovascular Therapeutics: How to Treat Theater: Coronary Artery Disease II Complex Coronary Intervention Using the Radial Approach; 2010.
33. Careers in Cardiology: How to get there, Bucknell University Pre-Medical Group, 2009.
34. Women Physicians in Interventional Cardiology: Personalized Medicine & Genomics, 2009.
35. Women in Interventional Cardiology: Risk Factor Treatment Post-PCI: How low to go, Medtronic Cardiovascular, 2009.
36. Update in Interventional Cardiology: New Devices, New Techniques, New Technology American College of Cardiology Grand Rounds Speaker
Unity Hospital - Rochester, NY. 2009
37. The Current State of Cardiovascular Treatment for Women. Gender Differences in Cardiovascular Device Trials, 2008.
38. Lifestyle & Diet to Lower Cardiovascular Risk, The Henry Hood Center for Health Research, 2008
39. Woman and Heart Disease from Risk Factors to Treatment: Does Gender Matter?
22nd Annual Horizons in Cardiac Rehabilitation, 2008
40. How A Women's Heart is Different
Cardiology News in 2008, The Henry Hood Center for Health Research, 2008
41. Treatment of Acute Myocardial Infarction
Internal Medicine Residents, 2008
42. Let's Talk About Women and Heart Disease
Women's Seminar, Spiritual Care Center, 2008
43. Cardiac Cath Handbook Live: A Hemodynamics Course – Part 3
ACC 08 and The SCAI Annual Scientific Sessions, 2008
44. Hemodynamics
Fellows Lecture Series, 2008
45. How To Prevent Heart Disease
Geisinger Health Plan, 2008
46. Questions and Answers with Heart Health Experts
Danville PA - Go Red Event, 2008
47. Know your Risks
American Heart Association 2008 Montour County, 2008
48. Access Site Challenges & Complications
Geisinger Fellows Lecture Series, 2008
49. Women & Revascularization: Do Women Always Do Worse?
APACVS 27th Annual Meeting, Ft. Lauderdale, FL, 2008
50. When to Use IVUS and FFR in the Catheterization Laboratory
Fellows Lecture Series, 2007
51. Acute Myocardial Infarction: An Epidemiologic View
Center For Health Research
Lunch & Learn Program, 2007.
52. IVUS and FFR in the Lab: When can it help?
2007 Cath Lab Basics, Boston, MA, 2007.
53. Pharmacology in the Lab
2007 Cath Lab Basics, Boston, MA, 2007.

54. Angiographic Challenges
2007 Cath Lab Basics, Boston, MA, 2007.
55. Developing a Career in Clinical Cardiovascular Research
WCR Summer Student Program-Annual Symposium
Weis Center for Health Research, 2007
56. Does Gender Matter in the Cath Lab?
Bloomsburg Hospital Grand Rounds, 2007
57. Women & Heart Disease: How to lower your risk
Tops Senior Circle talk
Lock Haven Hospital, 2007
58. Clinical and Translational Research in Cardiovascular Disease – How to Identify a Question and Design a Study, Annual Resident Research Day
The Center for Health Research, 2007
59. Does Gender Matter in the Catheterization Laboratory?
Getting to the Heart of the Matter: Cardiovascular Disease in Women, 2007
60. Cardiovascular Disease in Women: Preventable?
Women's Health and Cardiovascular Disease
Geisinger Wyoming Valley, 2007
61. How to Prevent and Treat Cardiovascular Risk Factors in Women as a PCP
Residents Talk, 2007
62. Women and Heart Disease: Primary and Secondary Prevention
J.C Blair Memorial Hospital, 2007
63. Women and Heart Disease: How to lower your risk.
J.C. Blair Memorial Hospital, 2007
64. The # 1 Killer of Women – Can we do more to lower the risk?
OBGYN Grand Rounds, 2007
65. Percutaneous Coronary Interventions in Women
Interventional Cardiology Conference, 2007
66. Women and Heart Disease: How you can lower your risk
American Association of University Women, 2007
67. Doppler Flow/FFR
Interventional Cardiology Conference, 2007
68. Vulnerable Plaque/Virtual Histology
Interventional Cardiology Conference, 2006
69. Moderator, American Heart Association, Scientific Sessions, 2006
70. Women's Heart Disease Update
20th Annual Horizons in Cardiac Rehabilitation, 2006
71. Acute MI: Primary and Rescue PCI
Interventional Cardiology Conference, 2006
72. Access: Tips, Techniques, Complications and Management
Interventional Cardiology Conference, 2006
73. Interventional Options for the Treatment of Atrial Fibrillation
Cardiology News in 2006 Plus: Heart Failure Mini-Symposium, 2006
74. Interventional Tools for Treatment Outside the Coronaries
Pennsylvania Osteopathic Medical Association District 6 Meeting, 2006
75. Women and Heart Disease: Signs and Symptoms of Heart Disease and Factors that Decrease the Risk, American Heart Association: Go Red for Women, 2006
76. Genomic Tools for Cardiovascular Research

- Science Innovation Synergy 2006, Course Faculty, Bellevue, WA, 2006
77. Women's Heart Disease Prevention
WNEP News Station, Heart Minute, 2006
 78. Women and Cardiovascular Disease: Gender Differences in Presentation and History
Susquehanna University, 2006
 79. Genomics in Cardiology, Now and in the Future
Cardiology for the Practitioner: 2005
Geisinger Medical Center – Danville, PA, 2005
 80. Hypertension, A Silent Killer
Call the Doctor, call in questions & answer
Televised live @ WVIA, 2006
 81. Moderator, Scientific Sessions of the American Heart Association, 2003
 82. Being Mentored: Early Career Development Forum
Kimberly A. Skelding, Valentine Fuster, Susan Tiukenoy
American Heart Association, Scientific Sessions, 2003
 83. Cardiovascular Genomics: Clinical Relevance
Grand Rounds Presentation, Geisinger Medical Center, Danville, PA, 2002
 84. Being Mentored; Early Career Development Forum
Kimberly A. Skelding, Valentine Fuster, Susan Tiukenoy
American Heart Association, Scientific Sessions, 2002
 85. How to be an Effective Clinical Teacher Co-Chair Early Career Development Forum
American Heart Association Scientific Sessions, November 2001
 86. What is Available from the College for Fellows in Training
KA Skelding, V Fuster, S Rahimtoola
27th Annual Symposium for Directors of Adult Cardiology Training Programs,
March 2001
 87. Acute Myocardial Infarction Angioplasty: When, Where, Who?
CL Grines, GW Stone, DA Cox, T Wharton, KA Skelding
Panel Discussion American College of Cardiology Scientific Sessions, March 2000